Trial reportDiabetes2008
Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
Trial report in Diabetes, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 74 citations in OpenAlex.
- Effect of vildagliptin on hepatic steatosis.The Journal of clinical endocrinology and metabolism · 2015 · on this mapTrial
- Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.Diabetologia · 2011 · on this mapTrial
- Trial
- Personalized Diabetes Therapy Part 2-Individual Diabetes Treatment (Standard of Care Plus, SOC+).Journal of personalized medicine · 2026Review
- Aetiology of type 2 diabetes: an experimental medicine odyssey.Diabetologia · 2025Review
- The Twin Cycle Hypothesis of type 2 diabetes aetiology: From concept to national NHS programme.Experimental physiology · 2025Review
- Aetiology of Type 2 diabetes in people with a 'normal' body mass index: testing the personal fat threshold hypothesis.Clinical science (London, England : 1979) · 2023Article
- Review
- Type 2 diabetes and remission: practical management guided by pathophysiology.Journal of internal medicine · 2021Review
- Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?Molecular metabolism · 2021Review
- NAFLD as a continuum: from obesity to metabolic syndrome and diabetes.Diabetology & metabolic syndrome · 2020Review
- Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man.Frontiers in endocrinology · 2019Review
- Calorie restriction for long-term remission of type 2 diabetes.Clinical medicine (London, England) · 2019Review
- Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice.Endocrinology · 2017Article
- Acute Effect of Metformin on Postprandial Hypertriglyceridemia through Delayed Gastric Emptying.International journal of molecular sciences · 2017Article
- Metabolic Surgery Could Restore Hepatic Glucose Metabolism: Results from F-18 Fluorodeoxyglucose Positron Emission Tomography.Obesity surgery · 2016Article
- Intracellular lipid accumulation and shift during diabetes progression.Wiener medizinische Wochenschrift (1946) · 2014Review
- Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restriction.Diabetes care · 2013Article
- Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm.Diabetic medicine : a journal of the British Diabetic Association · 2013Article
- Type 2 diabetes: etiology and reversibility.Diabetes care · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHepatic triglyceride is closely associated with hepatic insulin resistance and is known to be decreased by thiazolididinediones. We studied the effect of pioglitazone on hepatic triglyceride content and the consequent effect on postprandial endogenous glucose production (EGP) in type 2 diabetes. RESEARCH DESIGN AND
methodsTen subjects with type 2 diabetes on sulfonylurea therapy were treated with pioglitazone (30 mg daily) for 16 weeks. EGP was measured using a dynamic isotopic methodology after a standard liquid test meal both before and after pioglitazone treatment. Liver and muscle triglyceride levels were measured by (1)H magnetic resonance spectroscopy, and intra-abdominal fat content was measured by magnetic resonance imaging.
resultsPioglitazone treatment reduced mean plasma fasting glucose and mean peak postprandial glucose levels. Fasting EGP decreased after pioglitazone treatment (16.6 +/- 1.0 vs. 12.2 +/- 0.7 micromol . kg(-1) . min(-1), P = 0.005). Between 80 and 260 min postprandially, EGP was twofold lower on pioglitazone (2.58 +/- 0.25 vs. 1.26 +/- 0.30 micromol . kg(-1) . min(-1), P < 0.001). Hepatic triglyceride content decreased by approximately 50% (P = 0.03), and muscle (anterior tibialis) triglyceride content decreased by approximately 55% (P = 0.02). Hepatic triglyceride content was directly correlated with fasting EGP (r = 0.64, P = 0.01) and inversely correlated to percentage suppression of EGP (time 150 min, r = -0.63, P = 0.02). Muscle triglyceride, subcutaneous fat, and visceral fat content were not related to EGP. CONCLUSIONS Reduction in hepatic triglyceride by pioglitazone is very closely related to improvement in fasting and postprandial EGP in type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.